Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 2/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MC4R | P32245 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1449589 | 0.97 | FUCA1 (0.50) | FUCA1SIGMAR1ACHECYP1A2CYP3A4 | |
| SCHEMBL1022483 | 0.93 | OPRM1 (0.54) | FUCA1SIGMAR1ACHEMC4ROPRM1 | |
| Hydrochloric Acid SCHEMBL11776272 | 0.90 | OPRM1 (0.51) | FUCA1SIGMAR1ACHEMC4ROPRM1 | |
| SCHEMBL18713027 | 0.86 | FUCA1 (0.53) | FUCA1SIGMAR1ACHEMC4ROPRM1 | |
| SCHEMBL4737149 | 0.80 | FUCA1 (0.47) | FUCA1SIGMAR1ACHEMC4ROPRM1 | |
| SCHEMBL6959368 | 0.80 | FUCA1 (0.47) | FUCA1SIGMAR1ACHEALDH1A1MC4R | |
| SCHEMBL6957907 | 0.80 | FUCA1 (0.47) | FUCA1SIGMAR1ACHEMC4ROPRM1 | |
| SCHEMBL18711744 | 0.80 | S1PR1 (0.49) | FUCA1SIGMAR1ACHECYP2D6ALDH1A1 | |
| SCHEMBL9054403 | 0.80 | FUCA1 (0.58) | FUCA1SIGMAR1ACHEMC4R | |
| SCHEMBL14157505 | 0.78 | FUCA1 (0.56) | FUCA1SIGMAR1ACHECYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173658-B2 | Diagnosis test; mixing blood or other fluid sample with test compound; analyzing, calibration; central nervous system disorders; analgesics; antiinflamamtory agents; drug abuse; anxiolytic agents; cognition activators;Alzheimer's disease; Parkinson's disease; Huntington's disease; hyperactivity | NEUROSEARCH A/S (DK) | 2012-05-08 | — | — | US | disclosed |
| US-20110142758-A1 | INDOLYL-PYRIDAZINYL-DIAZABICYCLONONANE DERIVATIVES IN LABELLED AND UNLABELLED FORM AND THEIR USE IN DIAGNOSTIC METHODS | NEUROSEARCH A/S (DK) | 2011-06-16 | — | — | US | disclosed |
| US-20110092487-A1 | NOVEL 3,8-DIAZA-BICYCLO[3.2.1]OCTANE-AND 3,9-DIAZA-BICYCLO[3.3.1]-NONANE-3-CARBOXYLIC ACID ESTER DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2011-04-21 | — | — | US | disclosed |
| EP-1863819-B1 | DIAZABICYCLIC ARYL DERIVATIVES AND THEIR USE AS CHINOLINERGIC LIGANDS AT THE NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH AS (DK) | 2011-01-12 | — | — | EP | disclosed |
| EP-2246352-A1 | Novel diazabicyclic aryl derivatives and their medical use | NeuroSearch AS (DK) | 2010-11-03 | — | — | EP | disclosed |
| EP-1963323-B1 | NOVEL DIAZABICYCLIC ARYL DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH AS (DK) | 2010-07-14 | — | — | EP | disclosed |
| US-7662812-B2 | Diazabicyclic aryl derivatives and their use as chinolinergic ligands at nicotinic acetylcholine receptors | NEUROSEARCH A/S (DK) | 2010-02-16 | — | — | US | disclosed |
| US-20080280912-A1 | Diagnosis test; mixing blood or other fluid sample with test compound; analyzing, calibration; central nervous system disorders; analgesics; antiinflamamtory agents; drug abuse; anxiolytic agents; cognition activators;Alzheimer's disease; Parkinson's disease; Huntington's disease; hyperactivity | NEUROSEARCH A/S | 2008-11-13 | — | — | US | disclosed |
| EP-1963323-A1 | NOVEL DIAZABICYCLIC ARYL DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2008-09-03 | — | — | EP | disclosed |
| US-20080146582-A1 | disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances | NEUROSEARCH A/S (DK) | 2008-06-19 | — | — | US | disclosed |
| EP-1863819-A2 | DIAZABICYCLIC ARYL DERIVATIVES AND THEIR USE AS CHINOLINERGIC LIGANDS AT THE NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH A/S (DK) | 2007-12-12 | — | — | EP | disclosed |
| WO-2007065892-A1 | NOVEL DIAZABICYCLIC ARYL DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2007-06-14 | — | — | WO | disclosed |
| WO-2006087306-A2 | DIAZABICYCLIC ARYL DERIVATIVES AND THEIR USE AS CHOLINERGIC LIGANDS AT THE NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH A/S (DK) | 2006-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146582-A1 | disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances | CHRNA6, CHRNA10, CHRNA2 | FUCA1 670/4885SIGMAR1 130/4885ACHE 13/4885 |
| US-20110092487-A1 | NOVEL 3,8-DIAZA-BICYCLO[3.2.1]OCTANE-AND 3,9-DIAZA-BICYCLO[3.3.1]-NONANE-3-CARBOXYLIC ACID ESTER DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | SLC18A2, SLC6A2, SLC18A3 | FUCA1 2894/4885SIGMAR1 48/4885ACHE 347/4885 |
| US-20080280912-A1 | Diagnosis test; mixing blood or other fluid sample with test compound; analyzing, calibration; central nervous system disorders; analgesics; antiinflamamtory agents; drug abuse; anxiolytic agents; cognition activators;Alzheimer's disease; Parkinson's disease; Huntington's disease; hyperactivity | ACHE, CHRNA6, CHRNA10 | FUCA1 791/4885SIGMAR1 251/4885ACHE 1/4885 |
| US-20110142758-A1 | INDOLYL-PYRIDAZINYL-DIAZABICYCLONONANE DERIVATIVES IN LABELLED AND UNLABELLED FORM AND THEIR USE IN DIAGNOSTIC METHODS | CNR2, CNR1, HTR3E | FUCA1 1744/4885SIGMAR1 326/4885ACHE 1914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.